

## First quarter 2006 consolidated sales revenues

Paris, France, May 10, 2006 – press release 2006/03

Cerep (Eurolist: Cerep) consolidated sales revenues for the first quarter in 2006 amounted to EUR 13.19 million, compared to EUR 12.11 million for the first quarter 2005, reflecting an increase of 8.9%.

Details of segment sales revenues (drug discovery service and collaboration activities and clinical service activities), along with results before financial items and taxes will be released, as scheduled, on May 11, 2006, after market closes.

### ■ **Contacts**

Thierry Jean, Chairman & CEO  
Jean-Yves Latombe, Chief Financial Officer  
Sophie Macault, General Counsel & Corporate Secretary  
Tel. +33 (0)1 45 64 44 60  
fincom@cerep.fr

**Code ISIN FR0004042232**  
**Euronext Paris**  
**Eurolist - Local Securities**

Cerep SA  
155 boulevard Haussmann  
75008 Paris  
France  
tel + 33(0)1 45 64 44 60  
fax +33(0)1 45 64 44 64  
e-mail: fincom@cerep.fr  
**www.cerep.com**

Cerep's mission is to provide pharmaceutical companies with high quality services in drug discovery and drug development as well as drug candidates at different preclinical and clinical stages. Cerep provides solutions allowing faster and cost effective drug discovery by identifying at early stages the most promising drug candidates as well as eliminating those compounds likely to fail in development. Cerep's integrated platform encompasses a complete range of technologies including chemistry, biology, and informatics.

Cerep's technologies benefit to more than 360 pharmaceutical and biotechnological companies worldwide including most of the top pharmaceutical firms. Cerep's drug pipeline includes collaborative drug candidates developed with Sanofi-Aventis and Bristol-Myers Squibb (with two compounds in clinical trials for immuno-inflammatory disorders), as well as products discovered on its own (including one compound in phase I/II clinical trial in the field of cancer). Cerep's development strategy aims at self-financing its research.

*Statements included in this press release which are not historical in nature are intended to be, and are hereby identified as, "forward-looking statements" for purposes of the safe harbor provided by Section 21E of the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The company cautions readers that forward-looking statements, including without limitation those relating to the company's future operations and business prospects, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward-looking statements. Factors that may affect future operations and business prospects include, but are not limited to, clinical and scientific results and developments concerning corporate collaborations and the company's proprietary rights and other factors described in the company's Document de référence.*